Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/Korwcs7tEgI/221851.php
Saturday, 9 April 2011
T-DM1 Significantly Improved Progression-Free Survival In Randomized Phase II Trial
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that Roche has disclosed positive top-line results from the first randomized trial assessing trastuzumab emtansine (T-DM1, previously known as trastuzumab-DM1) in HER2-positive metastatic breast cancer (MBC). T-DM1 consists of ImmunoGen's DM1 cancer cell-killing agent attached using the Company's linker to the HER2-targeting antibody, trastuzumab, developed by Genentech, a member of the Roche Group...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment